Evidence map›Paper›PMID 37943358›Full record

ArticleJournal of cancer research and clinical oncology2023

Identification of circulating miRNA as early diagnostic molecular markers in malignant glioblastoma base on decision tree joint scoring algorithm.

Fei Su, Yueyang Liu, Yonghua Zong, Ziyu Gao, Guiqin Zhou, Chao Deng, Yuyu Liu, Yue Zeng, Xiaoyan Ma, Yongxia Wang and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Fei Su *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. sufei0999@ems.hrbmu.edu.cn.
Yueyang Liu *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yonghua Zong *Department of Modern Medicine, University of Tibetan Medicine, Lhasa, 850000, China.
Ziyu GaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Guiqin ZhouDepartment of Immunology, Harbin Medical University, Harbin, 150081, China.
Chao DengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yuyu LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yue ZengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Xiaoyan MaDepartment of Anatomy, Harbin Medical University, Harbin, 150081, China.
Yongxia WangDepartment of Anatomy, Harbin Medical University, Harbin, 150081, China.
Yinwei WuDepartment of Anatomy, Harbin Medical University, Harbin, 150081, China.
Fusheng XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Lili GuanDepartment of Information Management, Shanghai Lixin University of Accounting and Finance, Shanghai, 200438, China. guanll@lixin.edu.cn.
Baoquan LiuDepartment of Anatomy, Harbin Medical University, Harbin, 150081, China. 100549@hrbmu.edu.cn.
Harbin Medical University · CNTibetan Traditional Medical College · CNShanghai Lixin University of Accounting and Finance · CN

Funding

China Postdoctoral Science Foundation 2019M651298National Nature Science Foundation of China 61801151Natural Science Foundation of Heilongjiang Province LH2021F053Natural Science Foundation of Heilongjiang Province LH2023H013Postdoctoral Foundation of Heilongjiang Province LBH-Z18129Postdoctoral Foundation of Heilongjiang Province LBH-Z18187the construction project of doctoral program in Traditional Chinese Medicine (Tibetan Medicine) in University of Tibetan Medicine BSDJS-20-07
6 · The paper itself

Abstract

purposeThe lack of clinical markers prevents early diagnosis of glioblastoma (GBM). Many studies have found that circulating microRNAs (miRNAs) can be used as early diagnostic markers of malignant tumours. Therefore, the identification of novel circulating miRNA biomolecular markers could be beneficial to clinicians in the early diagnosis of GBM.

methodsWe developed a decision tree joint scoring algorithm (DTSA), systematically integrating significance analysis of microarray (SAM), Pearson hierarchical clustering, T test, Decision tree and Entropy weight score algorithm, to screen out circulating miRNA molecular markers with high sensitivity and accuracy for early diagnosis of GBM.

resultsDTSA was developed and applied for GBM datasets and three circulating miRNA molecular markers were identified, namely, hsa-miR-2278, hsa-miR-555 and hsa-miR-892b. We have found that hsa-miR-2278 and hsa-miR-892b regulate the GBM pathway through target genes, promoting the development of GBM and affecting the survival of patients. DTSA has better classification effect in all data sets than other classification algorithms, and identified miRNAs are better than existing markers of GBM.

conclusionThese results suggest that DTSA can effectively identify circulating miRNA, thus contributing to the early diagnosis and personalised treatment of GBM.

Indexed as

Brain NeoplasmsCirculating MicroRNAGlioblastomaMicroRNAsDecision TreesHumansCirculating MicroRNAMicroRNAsCirculating miRNADecision treeEarly diagnosisGlioblastomaNon-invasive

Identifiers

PMID37943358
PMCPMC11797510
OpenAlexW4388523990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.